- Home
- VERV vs AMLX Comparison
VERV vs AMLX Comparison
Compare VERV & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERV
- AMLX
- Stock Information
- Founded
- VERV 2018
- AMLX 2014
- Country
- VERV United States
- AMLX United States
- Employees
- VERV N/A
- AMLX N/A
- Industry
- VERV Medicinal Chemicals and Botanical Products
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- VERV Health Care
- AMLX Health Care
- Exchange
- VERV Nasdaq
- AMLX Nasdaq
- Market Cap
- VERV 475.0M
- AMLX 481.9M
- IPO Year
- VERV 2021
- AMLX 2022
- Fundamental
- Price
- VERV $7.28
- AMLX $3.30
- Analyst Decision
- VERV Strong Buy
- AMLX Buy
- Analyst Count
- VERV 4
- AMLX 7
- Target Price
- VERV $25.75
- AMLX $7.60
- AVG Volume (30 Days)
- VERV 1.3M
- AMLX 748.4K
- Earning Date
- VERV 02-28-2025
- AMLX 03-04-2025
- Dividend Yield
- VERV N/A
- AMLX N/A
- EPS Growth
- VERV N/A
- AMLX N/A
- EPS
- VERV N/A
- AMLX N/A
- Revenue
- VERV $24,396,000.00
- AMLX $196,485,000.00
- Revenue This Year
- VERV $106.46
- AMLX N/A
- Revenue Next Year
- VERV N/A
- AMLX N/A
- P/E Ratio
- VERV N/A
- AMLX N/A
- Revenue Growth
- VERV 219.91
- AMLX N/A
- 52 Week Low
- VERV $4.31
- AMLX $1.58
- 52 Week High
- VERV $19.34
- AMLX $19.95
- Technical
- Relative Strength Index (RSI)
- VERV 47.08
- AMLX 39.44
- Support Level
- VERV $7.44
- AMLX $3.42
- Resistance Level
- VERV $9.31
- AMLX $3.65
- Average True Range (ATR)
- VERV 0.67
- AMLX 0.26
- MACD
- VERV -0.12
- AMLX 0.00
- Stochastic Oscillator
- VERV 14.01
- AMLX 2.94
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.